Cinaciguat

• CAT Number: I003178
• CAS Number: 329773-35-5
• Molecular Formula: C36H39NO5
• Molecular Weight: 565.7
• Purity: ≥95%
• Target: Guanylate Cyclase
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IUPAC Name: 4-[[4-carboxybutyl-[2-[2-[[4-(2-phenylethyl)phenyl]methoxy]phenyl]ethyl]amino]methyl]benzoic acid
• InChI: InChI=1S/C36H39NO5/c38-35(39)12-6-7-24-37(26-30-19-21-33(22-20-30)36(40)41)25-23-32-10-4-5-11-34(32)42-27-31-17-15-29(16-18-31)14-13-28-8-2-1-3-9-28/h1-5,8-11,15-22H,6-7,12-14,23-27H2,(H,38,39)(H,40,41)
• InChIKey: WPYWMXNXEZFMAK-UHFFFAOYSA-N
• SMILES: C1=CC=C(C=C1)CCC2=CC=C(C=C2)COC3=CC=CC=C3CCN(CCCCC(=O)O)CC4=CC=C(C=C4)C(=O)O

Cinaciguat (Cat.No:I003178) is a novel drug that acts as a stimulator of soluble guanylate cyclase (sGC), an enzyme involved in the regulation of nitric oxide signaling. By stimulating sGC, cinaciguat enhances the production of cyclic guanosine monophosphate (cGMP), leading to vasodilation and relaxation of blood vessels. This mechanism of action makes cinaciguat a potential therapeutic option for conditions such as pulmonary hypertension and heart failure. Clinical studies are underway to explore its efficacy and safety in treating these cardiovascular disorders.

Reference

[1]. Mihai Gheorghiade1, Stephen J. Greene, Gerasimos Filippatos, et al. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur J Heart Fail (2012) 14 (9): 1056-1066.
[2]. Marc Chester, Gregory Seedorf, Pierre Tourneux, et al. Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension. AJP – Lung Physiol , 2011 ,301(5): L755-L764.
[3]. Marc Chester, Pierre Tourneux, Greg Seedorf, et al. Cinaciguat, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus. AJP – Lung Physiol August 2009, 297 (2): L318-L325.
[4]. Harald Lapp, Veselin Mitrovic, Norbert Franz, et al. Cinaciguat (BAY 58-2667) Improves Cardiopulmonary Hemodynamics in Patients With Acute Decompensated Heart Failure. Circulation.2009; 119: 2781-2788
[5]. Reiner Frey, Wolfgang Mück, Sigrun Unger, et al. Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of the Soluble Guanylate Cyclase Activator Cinaciguat (BAY 58-2667) in Healthy Male Volunteers. J Clin Pharmacol December 2008 vol. 48 no. 12 1400-1410